Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. News
  7. Summary
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agenus : MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

07/28/2021 | 08:31am EDT

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. MiNK is a subsidiary of Agenus Inc. (NASDAQ: AGEN).

This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the "Securities Act"), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com


Primary Logo

Source: Agenus Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about AGENUS INC.
09/17AGENUS : ESMO 2021 - Agenus Presents Updates on Balstilimab Plus Zalifrelimab Combination
PU
09/17ABCELLERA BIOLOGICS : Health Care Stocks Down to End Week
MT
09/17Health Care Stocks Mixed Premarket Friday
MT
09/17AGENUS : Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 T..
MT
09/16Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in..
GL
09/14INSIDER SELL : Agenus
MT
09/10AGENUS : New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Co..
AQ
09/10Agenus Inc. Announces New Subsidiary, SaponiQx
CI
09/09AGENUS : to Participate in September Investor Conferences
AQ
09/07AGENUS : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to..
MT
More news
Analyst Recommendations on AGENUS INC.
More recommendations
Financials (USD)
Sales 2021 263 M - -
Net income 2021 -95,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,4x
Yield 2021 -
Capitalization 1 375 M 1 375 M -
Capi. / Sales 2021 5,22x
Capi. / Sales 2022 13,9x
Nbr of Employees 359
Free-Float 87,2%
Chart AGENUS INC.
Duration : Period :
Agenus Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,90 $
Average target price 10,00 $
Spread / Average Target 69,5%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Jennifer S. Buell President & Chief Operating Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Marc van Dijk Chief Technology Officer
Steven OĺDay Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.85.53%1 375
MODERNA, INC.311.74%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.01%50 254
CELLTRION, INC.-23.54%33 124
SEAGEN INC.-7.88%30 241